TSE:PLB - Paladin Labs Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Paladin Labs Inc. is a specialty pharmaceutical company focused on developing, acquiring, in-licensing, marketing and distributing pharmaceutical products. The Company's product portfolio includes Tridural, Abstral and Trelstar. Tridural is a once-a-day tramadol product indicated as a first-line therapy for adults with moderate pain requiring several days or more of treatment. Abstral is a sublingual tablet used for the management of breakthrough cancer pain in patients who are already tolerant to other opioid analgesics. Trelstar is an injectable, luteinizing hormone releasing hormone agonist indicated for the palliative treatment of prostate cancer and endometriosis. In July 2013, the Company became the sole holder of Allon Therapeutics Inc. In September 2013, Blackstar Group SE announced that it has sold remaining 13.4% interests in Litha Healthcare Group Limited (Litha) to Paladin Labs Inc. Effective January 1, 2014, Paladin Labs Inc. acquired Triton Pharma Inc.

Receive PLB News and Ratings via Email

Sign-up to receive the latest news and ratings for PLB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange TSE
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolTSE:PLB
Previous Symbol
CUSIPN/A
Phone+1-514-3401112

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market CapC$0.00
OptionableNot Optionable

Paladin Labs (TSE:PLB) Frequently Asked Questions

What is Paladin Labs' stock symbol?

Paladin Labs trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PLB."

Has Paladin Labs been receiving favorable news coverage?

Media headlines about PLB stock have trended somewhat positive on Sunday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Paladin Labs earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the next several days.

How do I buy shares of Paladin Labs?

Shares of PLB and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Paladin Labs' official website?

The official website for Paladin Labs is http://www.paladinlabs.com.

How can I contact Paladin Labs?

Paladin Labs' mailing address is 100 Alexis-Nihon Blvd Suite 600, SAINT-LAURENT, QC H4M 2P2, Canada. The specialty pharmaceutical company can be reached via phone at +1-514-3401112.


MarketBeat Community Rating for Paladin Labs (TSE PLB)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  63 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  165
MarketBeat's community ratings are surveys of what our community members think about Paladin Labs and other stocks. Vote "Outperform" if you believe PLB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel